Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

Study Yields Rich Dossier of Cancer-Linked Protein's Associates

(Brown University) Oct 24, 2016 - By developing an atomic-scale picture of how the cancer-linked enzyme PP2A binds to other proteins, Brown University researchers have developed a new list of nearly 100 of its potential partners.
read press release 



Stability of Exhausted T Cells Limits Durability of Cancer Checkpoint Drugs

(Penn Medicine) Oct 27, 2016 - Checkpoint inhibitor drugs that boost the immune system to fight cancer owe part of their existence to infectious diseases. Microbes that cause diseases like HIV, malaria, and hepatitis C exploit and often activate the same checkpoint pathways -- cell surface receptors such as CTLA4 and PD-1 -- to slow immune cells and prevent their elimination by the host.
read press release 



VP Biden's Radical Plan To Exponentially Speed Up Cancer Innovation

(Forbes) Oct 27, 2016 - This week, StartUp Health CEO Steven Krein, Cleveland Clinic CEO and President Dr. Toby Cosgrove and Vice President of the United States Joe Biden, kicked off the 14th annual Medical Innovation Summit, and shared an urgent message with nearly 2,000 health leaders, CEOs, and entrepreneurs: it’s possible to exponentially speed up the progress in solving big health challenges like ending cancer, ensuring access to care, and improving the wellbeing of people worldwide.
read article 



J&J Loses Third Trial Over Cancer Link to Talcum Powder

(Bloomberg) Oct 27, 2016 - Johnson & Johnson lost a third straight trial over claims its talcum powder can cause ovarian cancer with a St. Louis jury awarding a California woman more than $70 million.
read article 



How Scientists Proved the Wrong Man Was Blamed for Bringing HIV to the U.S.

(Los Angeles Times/Science Now blog) Oct 26, 2016 - The Canadian flight attendant widely blamed for bringing HIV to the United States and triggering an epidemic that has killed nearly 700,000 people has been exonerated by science, more than 30 years after his death.
read article (free registration required) 



Health Law Tax Penalty? I’ll Take It, Millions Say

(New York Times) Oct 26, 2016 - The architects of the Affordable Care Act thought they had a blunt instrument to force people — even young and healthy ones — to buy insurance through the law’s online marketplaces: a tax penalty for those who remain uninsured.
read article 



Public Ranks Drug Costs and Sufficient Provider Networks Ahead of Affordable Care Act Changes as Health Care Priorities for Next President and Congress to Address

(Kaiser Family Foundation) Oct 27, 2016 - As the 2016 campaign nears its end, the latest Kaiser Health Tracking Poll examines the public’s view on health care priorities for the next president and Congress.
read press release 



The First Important Test in the Drug-Price Hike Controversy Is Happening in California

(Business Insider) Oct 26, 2016 - A rash of controversial drug price hikes has triggered protests and sparked calls by Hillary Clinton, lawmakers and consumer groups for regulatory action as early as next year.
read article 



Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma

(Yahoo! Finance) Oct 27, 2016 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has entered into a clinical trial collaboration agreement with Merck & Co., Inc., for the assessment of Adaptimmune’s NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in combination with MSD’s anti-programmed death-1 (PD-1) inhibitor, KEYTRUDA® (pembrolizumab), in patients with multiple myeloma.
read article 



NCI Collaborates With Multiple Myeloma Research Foundation

(NCI) Oct 28, 2016 - The National Cancer Institute announced a collaboration with the Multiple Myeloma Research Foundation (MMRF) to incorporate MMRF's wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons, a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology.
read press release 



Varian and McKesson Specialty Health Announce Strategic Agreement for Advanced Radiotherapy Equipment and Software

(US Oncology) Oct 26, 2016 - Varian Medical Systems and McKesson Specialty Health today announced a strategic agreement for the deployment and servicing of Varian advanced radiotherapy equipment and software over a three-year period across The US Oncology Network and Vantage Oncology affiliated sites of care.
read corporate press release 



NantHealth Announces Immunotherapy Clinical Trials in the Mid-Atlantic, First Whole Genomics Supercomputing Medical Reasoning Engine Helps Oncologists Make Informed Treatment Decisions for Cancer Patients

(Yahoo! Finance) Oct 26, 2016 - Panel discussion and press conference with Dr. Patrick Soon-Shiong, Founder and CEO of NantHealth, Inc. (NH), a leading next-generation, evidence-based, personalized healthcare company, and esteemed leadership of Horizon Blue Cross Blue Shield of New Jersey who will cover GPS Cancer tests to advance molecular science for its members enrolled in investigational studies for key cancer types—non-small cell lung cancer, breast cancer, colon cancer, and cancer of unknown primary—across leading health systems in the mid-Atlantic
read article 



MDxHealth Announces Positive Coverage Policy With Fourth-Largest Health Insurer In The United States

(TheStreet) Oct 27, 2016 - MDxHealth SA today announced that Health Care Services Corporation (HCSC) has issued coverage for patients meeting the eligibility criteria established under the positive medical policy on the ConfirmMDx® for Prostate Cancer test.
read article 



NICE Nods for Tagrisso, Cimzia and Zepatier

(PharmaTimes [UK]) Oct 27, 2016 - AstraZeneca's Tagrisso (osimertinib) has been recommended as an option for use wihin the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor.
read article 



Bristol Hikes 2016 Profit Forecast as Top Drugs Deliver, Shares Jump

(Reuters) Oct 27, 2016 - Bristol-Myers Squibb Co, whose shares have plunged since its new Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after surprisingly strong quarterly sales of other leading medicines.
read article 



Employers Express Their Concerns With Cancer Care at the COA Summit

(AJMC) Oct 26, 2016 - With discussions around cancer care quality and cost, payers—either health plans or employers—are concerned with what it means for them and for the patient. At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), held October 24-25, 2016, in Tyson’s Corner, Virginia, 2 employer groups and a provider participated on a panel to provide practical insight into the extraordinary challenges and decisions faced by employers and employees with a cancer diagnosis.
read article 



New Data Show that Use of Percepta® Bronchial Genomic Classifier Reduces Surgeries and Other Costly Procedures in Lung Cancer Screening and Diagnosis

(Yahoo! Finance) Oct 26, 2016 - Veracyte, Inc. today announced new data from a prospective, multicenter clinical utility study showing that use of the Percepta Bronchial Genomic Classifier to resolve inconclusive diagnostic results in patients undergoing evaluation for suspected lung cancer led to a significant reduction in surgeries and other costly, invasive procedures.
read article 



Mutations in Bone Cells Can Drive Leukemia in Neighboring Stem Cells

(Emory University) Oct 26, 2016 - Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta have found.
read press release 



Searching the Human Immune System for Clues to Cancer

(MIT News) Oct 26, 2016 - After a young man with acute leukemia was treated successfully with traditional chemotherapy, he found himself facing a tough decision.
read article 



Clinical and Patient-Reported Outcomes Are the Same for Older and Younger Women Who Have Breast Reconstruction after Mastectomy for Breast Cancer

(American College of Surgeons) Oct 26, 2016 - The most comprehensive study of its kind to date found that older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women without a significant increase in the risk for complications.
read press release 



Drug Targeting Tumor Metabolism Discovered by MD Anderson's Institute for Applied Cancer Science Enters Clinical Trial

(MD Anderson) Oct 26, 2016 - The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759.
read press release 



Mayo Clinic Study Shows That Choice of Medical Center Impacts Life Expectancy of Multiple Myeloma Patients

(Mayo Clinic) Oct 26, 2016 - People diagnosed with multiple myeloma are more likely to live longer if they are treated at a medical center that sees many patients with this blood cancer. Mayo Clinic researchers published these findings today in the Journal of Clinical Oncology.
read article 



Promising Blood Test Fails to Yield Clues About Best Strategies for Bladder Cancer Treatment

(Penn Medicine) Oct 27, 2016 - A blood test that has shown promise in predicting how cancer will progress and what treatments will be most effective for a given patient may not be reliable for either, according to a new Penn Medicine study published this week in Cancer, a peer-reviewed journal of the American Cancer Society.
read press release 



Cancer Survivors Take More Psych Meds Than Other People

(Reuters Health) Oct 26, 2016 - People who live through a bout with cancer are more likely to use medication for anxiety and depression than those without a history of malignancies, a U.S. study suggests.
read article 



AstraZeneca Shares Decline After Recruitment Paused in Head and Neck Cancer Trial

(StreetInsider) Oct 27, 2016 - AstraZeneca declined Thursday, falling over 4% intraday. Chatter suggested weakness was related to a halt in recruitment for its trial evaluating its IO combo in head and neck cancer.
read article